Horizon 2020 Funding
HiberGene is the lead member of an international consortium which was awarded a grant of €930,000 from Horizon 2020, the EU programme for research and innovation, to support the development and commercialisation of a COVID-19 molecular test.
Introducing the other members of the consortium:
Ospedale Policlinico San Martin
A 1,200-bed university hospital in Genoa (pop. 650,000), the tertiary adult-care reference hospital of Liguria Region. The hospital hosts the regional reference laboratory for diagnosis and surveillance of seasonal and pandemic respiratory diseases, and is a member of the Italian influenza surveillance network (INFLUNET).
Queen’s University Belfast
An internationally renowned university ranked 9th in the word for international research collaboration, QUB is home to the Wellcome-Wolfson Institute For Experimental Medicine, a prestigious hub of excellence for infectious respiratory diseases.
Medcaptain Medical Technology Ltd.
Founded in 2011, Medcaptain is a leader in the medical device space in China, with an international presence. Specialising in the fields of medication delivery, IVD, airway management and DVT prevention, the company has been granted over 200 patents and the copyright for 15 software applications.
RNA-based Positive Control material was prepared at QUB for use in evaluation of initial prototype assay kits.
Together with the other consortium members, a range of additional studies aimed at extending the clinical and commercial application of the HGCOVIDR product are planned. These studies include the addition of new specimen types, patient populations, and test algorithms.